<DOC>
	<DOCNO>NCT01623206</DOCNO>
	<brief_summary>The objective study find maximum tolerate dose preliminary efficacy desmopressin haemostatic agent , administer patient colorectal cancer rectal bleeding , specific oncologic treatment surgery and/or chemotherapy and/or radiotherapy .</brief_summary>
	<brief_title>Desmopressin ( DDAVP ) Patients With Colorectal Cancer Rectal Bleeding</brief_title>
	<detailed_description>Colorectal cancer third cause cancer men woman , accord data recently publish United Sates , third cause death population . Ninety percent ( 90 % ) patient symptoms time diagnosis , rectal bleeding frequent one ( 50 % case ) . Bleeding , mainly mild moderate , specific treatment , stag disease , control . Desmopressin , synthetic analogue vasopressin , selective agonist receptor V2 vasopressin , induce , among others , haemostatic effect . Interestingly , expression receptor describe human gastrointestinal tract , include colon rectum colorectal tumor . Moreover , desmopressin show significant antitumor activity preclinical murine model colorectal cancer . This dose finding study , investigate new indication desmopressin haemostatic agent patient colorectal cancer mild moderate rectal bleeding .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>Patients &gt; 18 &lt; 80 year age sign informed consent form Histological diagnosis rectal adenocarcinoma localize , locally advanced metastatic Treatment indication chemotherapy and/or radiotherapy and/or surgery accord disease stage Rectal bleeding associate primary tumor within 48 hour prior study entry Acceptable organ function able participate study , perform within 14 day prior admission ; define follow parameter : Electrocardiogram ( ECG ) without significant clinical abnormality Haemoglobin great equal 8 g/dL Total leukocyte count great equal 4.0 x 10^9/L Absolute neutrophil count great equal 1.5 x 10^9/L Total platelet count great 100.0 x 10^9/L Total bilirubin less equal 1.5 time upper limit normality ( ULN ) Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) less equal 1.5 time upper limit normality ( ULN ) Creatinine clearance great 50 ml/min Performance status ( Eastern Cooperative Oncology Group [ ECOG ] ) less equal 2 Patients childbearing potential use one follow contraceptive method : intrauterine device , barrier method tubal ligation Colorectal cancer without bleed evidence Pregnancy lactation Use hormonal contraceptive treatment sexual hormone general Patients illnesses adequately control congestive heart failure , arterial blood pressure , unstable angina , severe cardiac arrhythmia , thromboembolic disease , diabetes 1 2 , hide coronary disease determine previous assessment Psychiatric disease imply patient incompetence Known hypersensitivity desmopressin vasopressin Severe von Willebrand disease ( vWD ) ( define vWF &lt; 10 % Ui/dl ) 2B vWD ( define increase platelet agregation induce ristocetin low concentration ) hemophilia A B carrier History seizures Renal insufficiency ( Creatinine clearance &lt; 50 ml/min ) , hyponatremia ( serum sodium low low limit normalityUNL ) previous history hyponatremia Syndrome inappropriate antidiuretic hormone secretion ( SIADH ) Positive serology hepatitis B , C know human immunodeficiency virus ( HIV ) infection Known liver disease ( cirrhosis , liver enzymes great equal 1.5 time upper limit normality total bilirubin great equal 1.5 time upper limit normality Active infection wich , accord investigator judgement , coud interfere patient safety Other malignancy , exception basal cell carcinoma , situ cervical carcinoma , tumour adequately treated diseasefree period great equal 5 year Patients receive receive investigational drug 30 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>